Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 14;22(1):919.
doi: 10.1186/s13063-021-05724-5.

Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial

Céline K Stäuble  1   2   3 , Markus L Lampert  2   3 , Samuel Allemann  2 , Martin Hatzinger  4 , Kurt E Hersberger  2 , Henriette E Meyer Zu Schwabedissen  1 , Christian Imboden  5 , Thorsten Mikoteit  4
Affiliations

Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial

Céline K Stäuble et al. Trials. .

Abstract

Background: It is known that only 50% of patients diagnosed with major depressive disorders (MDD) respond to the first-line antidepressant treatment. Accordingly, there is a need to improve response rates to reduce healthcare costs and patient suffering. One approach to increase rates of treatment response might be the integration of pharmacogenetic (PGx) testing to stratify antidepressant drug selection. The goal of PGx assessments is to identify patients who have an increased risk to experience adverse drug reactions or non-response to specific drugs. Especially for antidepressants, there is compiling evidence on PGx influencing drug exposure as well as response.

Methods: This study is an open-label, randomized controlled trial conducted in two study centers in Switzerland: (1) the Psychiatric Clinic of Solothurn and (2) the Private Clinic Wyss in Münchenbuchsee. Adult inpatients diagnosed with a unipolar moderate or severe depressive episode are recruited at clinic admission and are included in the study. If the adjustment to a new antidepressant pharmacotherapy is necessary, the participants are randomized to either Arm A (intervention group) or Arm B (control group). If no new antidepressant pharmacotherapy is introduced the participants will be followed up in an observational arm. The intervention is the service of pharmacist-guided pre-emptive PGx testing to support clinical decision making on antidepressant selection and dosing. As a comparison, in the control group, the antidepressant pharmacotherapy is selected by the treating physician according to current treatment guidelines (standard of care) without the knowledge of PGx test results and support of clinical pharmacists. The primary outcome of this study compares the response rates under antidepressant treatment after 4 weeks between intervention and control arm.

Discussion: The findings from this clinical trial are expected to have a direct impact on inter-professional collaborations for the handling and use of PGx data in psychiatric practice.

Trial registration: ClinicalTrials.gov NCT04507555 . Registered on August 11, 2020. Swiss National Clinical Trials Portal SNCTP000004015 . Registered August 18, 2020.

Keywords: Antidepressant; Depression; Pharmaceutical care; Pharmacogenomics; Psychiatry.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study procedures
See this image and copyright information in PMC

References

    1. Zajecka JM. Treating depression to remission. J Clin Psychiatry. 2003;64(Suppl 15):7–12. doi: 10.4088/JCP.v64n1019b. - DOI - PubMed
    1. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D Study Team Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. doi: 10.1176/appi.ajp.163.1.28. - DOI - PubMed
    1. Holsboer-Trachsler E, Hättenschwiler JA, Beck J, Brand S, Hemmeter UM, Keck ME, Rennhard S, Hatzinger M, Merlo M, Bondolfi G, Preisig M, Gehret A, Bielinski D, Seifritz E. Die Akutbehandlung depressiver Episoden. Swiss Medical Forum. 2016;16(35):716–724. doi: 10.4414/smf.2016.02704. - DOI
    1. Meyer Zu Schwabedissen HE. The role of pharmacogenomics in individualized medicine. In: Fischer T, Langanke M, Marschall P, Michl S, editors. Individualized medicine–ethical, economical and historical perspectives. Springer, Cham; 2014. P. 93-112.
    1. Owen RP, Sangkuhl K, Klein TE, Altman RB. Cytochrome P450 2D6. Pharmacogenet Genomics. 2009;19(7):559–562. doi: 10.1097/FPC.0b013e32832e0e97. - DOI - PMC - PubMed

Publication types

Substances

Associated data